Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Amy on +441494 818 052 or amyp@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Amy Pearce
Senior Account Manager
amyp@zenopa.com
+441494 818 052

Testimonials
I just wanted to say thank you for all the help you provided in finding me my current role. You demonstrated a great deal of knowledge and patience over the past year along with providing great advice...
Ricky, 2013

Merck Millipore and Proteomics International to ally on biomarker research

1 February 2012 00:00 in Scientific Company News


Merck Millipore has announced a new collaboration with Proteomics International to study biomarkers related to diabetic nephropathy.

The alliance will see Proteomics International assessing thirteen newly identified putative protein biomarkers using multiplex immunoassays from Merck Millipore, including proteins involved in metabolism, inflammation and oxidative stress.

Diabetic nephropathy is a potentially significant complication of diabetes that can lead to kidney failure, but screening for the condition is currently limited to use of the microalbumin test, which offers only limited efficacy.

The new biomarkers could be used to monitor the progression and prognosis of kidney disease in patients with diabetes far more effectively than is now possible.

Dr Jehangir Mistry, director of research and development at Merck Millipore, said: "We expect this opportunity will enable Merck Millipore to expand our substantial portfolio of Elisa and Milliplex multiplexed-bead based assays for diabetes and metabolic disease biomarkers."

In December 2011, the company expanded its product range with the launch of the SIRTainty Class III HDAC Assay, for use in the detection of sirtuin activity.ADNFCR-8000103-ID-801281135-ADNFCR

Other news stories from 01/02/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd